Asset Details
Do you wish to reserve the book?
Patient with TNBC with early relapse within 12 months from adjuvant treatment.
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Patient with TNBC with early relapse within 12 months from adjuvant treatment.
Do you wish to request the book?
Patient with TNBC with early relapse within 12 months from adjuvant treatment.
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Patient with TNBC with early relapse within 12 months from adjuvant treatment.
2024
Overview
Triple negative disease, defined by a lack of tumor cell expression of estrogen receptor, progesterone receptor and HER2, remains to date the worst prognosis subtype and especially in metastatic disease triple negative breast cancer is still un unmet clinical need. However, even in this setting, now we can use new drugs such as immunotherapy and antibodies drug conjugated to improve outcome. Particularly, sacituzumab govitecan is the first Ab drug conjugated demonstrating a significant improvement in terms of overall and progression free survival in patients affected by metastatic TNBC pretreated with 2-3 previous lines of therapy.
Publisher
Il Pensiero Scientifico Editore
Subject
